financetom
Business
financetom
/
Business
/
PhonePe hits 250 mn user mark, registers 925 mn transactions in October
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PhonePe hits 250 mn user mark, registers 925 mn transactions in October
Nov 2, 2020 4:28 AM

Flipkart-owned fintech platform PhonePe on Monday said it has crossed the 250 million registered user milestone. The company reported over 100 million monthly active users (MAU) and 2.3 billion app sessions in October, a statement said. ”PhonePe had a record month in October, processing 925 million transactions – its highest so far – with an annual TPV (total payment volume) run rate of USD 277 billion. PhonePe also processed 835 million UPI transactions in October, for a market-leading share of over 40 percent,” it added.

Sameer Nigam, CEO and founder of PhonePe, said the company has set a target of crossing 500 million registered users by December 2022. ”In line with our brand ethos of ’Karte Ja. Badhte Ja’, we continue to launch new and innovative products for every strata of Indian society, as well as enable digital payment acceptance across every merchant in every village and town in India,” he added.

PhonePe – which competes with the likes of Paytm, MobiKwik and Google Pay – allows users to send and receive money, recharge mobile and make utility payments as well as buy gold and make investments. It had also launched its ’Switch’ platform that allows customers can place orders on over 220 apps including Ola, Myntra, IRCTC, Goibibo, RedBus and Oyo.

Also Read

: Paytm Postpaid aims to double postpaid service users to 1.5 cr by March 2021

PhonePe is accepted at 13 million merchant outlets across 500 cities nationally.

First Published:Nov 2, 2020 1:28 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Teledyne's third-quarter profit rises on strong defense demand
Teledyne's third-quarter profit rises on strong defense demand
Oct 23, 2024
Oct 23 (Reuters) - U.S. defense firm Teledyne ( TDY ) on Wednesday reported a rise in third-quarter profit, driven by strong demand for marine instrumentation and aerospace electronics. Ongoing conflicts in the Middle East and the Russia-Ukraine war have led to a surge in defense spending by countries, benefiting companies such as Teledyne ( TDY ), Lockheed Martin (...
BRIEF-Zenatech Announces Software Company Acquisition Adding Significant Capabilities To Building Ai Drones
BRIEF-Zenatech Announces Software Company Acquisition Adding Significant Capabilities To Building Ai Drones
Oct 23, 2024
Oct 23 (Reuters) - ZenaTech Inc ( ZENA ): * ZENATECH ANNOUNCES A SOFTWARE COMPANY ACQUISITION ADDING SIGNIFICANT CAPABILITIES TO BUILDING AI DRONES * ZENATECH INC ( ZENA ) - TO ACQUIRE ZOOOFFICE INC. Source text for Eikon: Further company coverage: ...
Market Chatter: Meta Wins Shareholder Lawsuit Over Alleged False Child Safety Claims
Market Chatter: Meta Wins Shareholder Lawsuit Over Alleged False Child Safety Claims
Oct 23, 2024
08:14 AM EDT, 10/23/2024 (MT Newswires) -- Meta Platforms ( META ) won a shareholder lawsuit allegedly claiming that the tech giant made false child safety claims, Reuters reported late Tuesday, citing a court decision. The lawsuit, filed by plaintiff Matt Eisner, alleged that Meta misled stockholders in its proxy statement about the inability to ensure the safety of children...
Eli Lilly's Alzheimer's Treatment Donanemab Deemed Not Cost-Effective for NHS use, UK Health Body Says
Eli Lilly's Alzheimer's Treatment Donanemab Deemed Not Cost-Effective for NHS use, UK Health Body Says
Oct 23, 2024
08:12 AM EDT, 10/23/2024 (MT Newswires) -- Eli Lilly's ( LLY ) new treatment for mild Alzheimer's disease donanemab requires more evidence on its clinical and cost-effectiveness and cannot currently be considered good value for the UK's National Health Service, the National Institute for Health and Care Excellence said Wednesday. The treatment is licensed by the country's Medicines and Healthcare...
Copyright 2023-2026 - www.financetom.com All Rights Reserved